Evolocumab [Repatha]

[MAF] Evolocumab (Repatha) Injection In Prefilled Autoinjector 140 mg/mL

1. Additional clinical criteria applies

2. Treatment of patients with non-familial hypercholesterolemia or mixed dyslipidaemia, with atherosclerotic cardiovascular disease and additional risk factors and LDL-c level above 1.8 mmol/L despite maximal tolerated lipid-lowering therapy for at least 12 weeks. Subsidy only applies when evolocumab is dosed at 140 mg every 2 weeks.

3. Treatment of patients with heterozygous familial hypercholesterolemia, with atherosclerotic cardiovascular disease and LDL-c level above 1.8 mmol/L despite maximal tolerated lipid-lowering therapy for at least 12 weeks. Subsidy only applies when evolocumab is dosed at 140 mg every 2 weeks.

4. Treatment of patients with heterozygous familial hypercholesterolemia, without atherosclerotic cardiovascular disease, and LDL-c level above 2.6 mmol/L despite maximal tolerated lipid-lowering therapy for at least 12 weeks. Subsidy only applies when evolocumab is dosed at 140 mg every 2 weeks.

5. Treatment of patients with homozygous familial hypercholesterolemia with LDL-c level above 1.8 mmol/L despite maximal tolerated statin-lowering therapy for at least 12 weeks.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

02/01/2024 PCSK9 inhibitors for treating hypercholesterolaemia

The Ministry of Health’s Drug Advisory Committee has recommended:

• Evolocumab 140 mg/mL solution for injection in prefilled autoinjector for treating:

  • non-familial hypercholesterolaemia (non-FH) or mixed dyslipidaemia, with atherosclerotic cardiovascular disease (ASCVD) and additional risk factors and LDL-c level above 1.8 mmol/L despite maximal tolerated lipid-lowering therapy (LLT) for at least 12 weeks; or

  • heterozygous familial hypercholesterolaemia (HeFH), with ASCVD and LDL-c level above 1.8 mmol/L despite maximal tolerated LLT for at least 12 weeks; or

  • HeFH, without ASCVD, and LDL-c level above 2.6 mmol/L despite maximal tolerated LLT for at least 12 weeks; or

  • homozygous familial hypercholesterolaemia (HoFH) with LDL-c level above 1.8 mmol/L despite maximal tolerated statin-lowering therapy for at least 12 weeks.

Funding status

[R] Evolocumab 140 mg/mL solution for injection in prefilled autoinjector is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 November 2023.

[R] The dose of evolocumab for the treatment of non-FH or mixed dyslipidaemia and HeFH recommended for subsidy is 140 mg every 2 weeks. The dose restriction does not apply to HoFH.

[R] Evolocumab should be used in line with the additional clinical criteria listed in the Annex.

[NR] MAF assistance does not apply to any formulations or strengths of alirocumab or inclisiran for treating hypercholesterolaemia.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration